A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer-Reference-Cited by-同舟云学术

A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer

Published:2013-07-23 Issue:4 Volume:109 Page:920-925
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Ko A H,Tempero M A,Shan Y-S,Su W-C,Lin Y-L,Dito E,Ong A,Wang Y-W,Yeh C G,Chen L-T

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2013408.pdf

Reference19 articles.

1. Assaf E, Verlinde-Carvalho M, Delbaldo C, Grenier J, Sellam Z, Pouessel D, Bouaita L, Baumgaertner I, Sobhani I, Tayar C, Paul M, Culine S (2011) 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncology 80: 301–306.

2. Boeck S, Weigang-Kohler K, Fuchs M, Kettner E, Quietzsch D, Trojan J, Stotzer O, Zeuzem S, Lordick F, Kohne CH, Kroning H, Steinmetz T, Depenbrock H, Heinemann V (2007) Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial. Ann Oncol 18: 745–751.

3. Burris HA 3rd, Rivkin S, Reynolds R, Harris J, Wax A, Gerstein H, Mettinger KL, Staddon A (2005) Phase II trial of oral rubitecan in previously treated pancreatic cancer patients. Oncologist 10: 183–190.

4. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403–2413.

5. Chen LT, Chang TC, Cheng AL, Yang CH, Shiah HS, Chang JY, Yeh G (2008) Phase I study of liposome encapsulated irinotecan (PEP02) in advanced solid tumour patients. J Clin Oncol 26: 2565 (abstract).

Cited by 146 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic Therapy for Metastatic Pancreatic Cancer—Current Landscape and Future Directions;Current Oncology;2024-09-04

2. Safety and efficacy of liposomal irinotecan as the second-line treatment for advanced pancreatic cancer: A systematic review and meta-analysis;Critical Reviews in Oncology/Hematology;2024-09

3. Unlocking therapeutic precision: “Camptotheca acuminata, a traditional chinese herb tailored for phytonano-cancer theranostics”;Pharmacological Research - Modern Chinese Medicine;2024-06

4. A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma;European Journal of Cancer;2024-04

5. Integration of liposomal irinotecan in the first-line treatment of metastatic pancreatic cancer: try to do not think about the white bear;Therapeutic Advances in Medical Oncology;2024-01